Medical Devices maker Trivitron healthcare launches CoE at AMTZ Campus in Visakhapatnam
This CoE will implement research and innovation in the field of Metabolomics, Genomics, Newborn Screening, and Molecular Diagnostics and bring out cost-effective and affordable medical technology products and services.
Visakhapatnam: Trivitron Healthcare, a global manufacturer of medical devices, has recently announced the inauguration of its Centre of Excellence (CoE) with state-of-the-art R&D and Manufacturing facilities at AMTZ Campus here.
The Centre in Metabolomics, Genomics, Newborn Screening, and Molecular Diagnostics, was inaugurated by Prof. Ajay Kumar Sood, Principal Scientific Advisor to the Government of India and Prof. (Dr) Balram Bhargava, Former Director General, Indian Council of Medical Research in the presence of Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare, the Healthcare company said in a release here.
Speaking on the occasion, Dr Velu said "Trivitron is committed to providing futuristic applications by encompassing advanced R&D, which will be coupled with strong manufacturing capabilities under the supervision of leading scientists and industry experts in this centre.
This CoE will implement research and innovation in the field of Metabolomics, Genomics, Newborn Screening, and Molecular Diagnostics and bring out cost-effective and affordable medical technology products and services.
With 15 certified manufacturing facilities in India, USA, Finland, Turkey and China, Trivitron spearheads innovation in the field of In-Vitro Diagnostics, Medical Imaging and Critical Care Solutions, Dr Velu said.
By harnessing the enormous power of genomic research and Trivitron's expertise in advanced diagnostics, this Centre of Excellence will focus on creating unparalleled medical discoveries to transform healthcare delivery.
The new centre is equipped with state-of-art infrastructure to support the entire product & process development lifecycle at the respective domain-specific labs to achieve optimal scale-up to industrial production, he added.
IVD CE-approved kits for various newborn screening, infectious, non-infectious diseases and cancer markers based on RT-PCR, ELISA, Rapid cards/POCT, clinical chemistry and CLIA will be manufactured at this facility.
The major focus of this facility will be on the manufacturing of genomics-based kits and reagents. This will include the synthesis of customized primers and probes for RT-PCR-based screening kits, enzymes and master mixes.
The centre includes an Advanced Genomics and Molecular diagnostics facility for developing kits and reagents for Next Generation Sequencing (NGS) and Oligonucleotide synthesis (synthesis of customized primers and TaqMan Chemistry dual labelled probes), Protein Chemistry (design and expression of different recombinant enzymes and proteins), Cell culture and analytical lab.
The company plans to manufacture all the raw materials and components of molecular diagnostics, NBS, and NGS in-house following advanced protocols and research approaches.
The new centre of Trivitron will have provision to manufacture 300 million RT-PCR tests and over 70 million tests of Rapid Card/POCT per annum.
Additionally, more than 100 million tests can be manufactured for Genomics, ELISA, CLIA, NBS and other diagnostics kits, the release added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd